The Behcet Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Behcet Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Behcet Disease and features dormant and discontinued products.
GlobalData tracks six drugs in development for Behcet Disease by six companies/universities/institutes. The top development phase for Behcet Disease is phase ii with two drugs in that stage. The Behcet Disease pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Behcet Disease pipeline products market are: Amgen, Chugai Pharmaceutical and Iltoo Pharma.
The key targets in the Behcet Disease pipeline products market include Interleukin 2 Receptor, cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4A, and cAMP Specific 3′,5′ Cyclic Phosphodiesterase 4B.
The key mechanisms of action in the Behcet Disease pipeline product include Phosphodiesterase 4 Inhibitor with one drug in Phase III. The Behcet Disease pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Behcet Disease pipeline products market including Small Molecule, and Antibody.
Behcet Disease overview
Behcet disease, sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals. More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.
For a complete picture of Behcet Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
